Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/193208| Title: | Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy |
| Author: | Ortiz-Maldonado, Valentín Rives, Susana Español Rego, Marta Alonso Saladrigues, A. Montoro, Mercedes Magnano, Laura Giné Soca, Eva Pascal i Capdevila, Mariona Díaz Beyà, Marina Castella, Maria Català, Albert Faura, Anna Rodríguez Lobato, Luis Gerardo Oliver Caldés, Aina Martínez Roca, Alexandra Rovira, Montserrat González Navarro, Europa Azucena Ortega, Juan Ramón Cid Vidal, Joan Lozano, Miquel García Rey, Enric Fernández, Sara Castro Rebollo, Pedro Jordán García, Iolanda Villamor i Casas, Neus Aymerich Gregorio, Marta Torrebadell, Montserrat Deyá, Angela Fernández de Larrea Rodríguez, Carlos José Benítez-Ribas, Daniel Trias, Esteve Varea, Sara Calvo Rojas, Gonzalo Esteve, Jordi Urbano Ispizua, Álvaro Juan, Manel Delgado, Julio (Delgado González) |
| Keywords: | Leucèmia limfocítica crònica Cèl·lules canceroses Teràpia cel·lular Antígens CD Immunoteràpia Receptors cel·lulars Chronic lymphocytic leukemia Cancer cells Cellular therapy CD antigens Immunotheraphy Cell receptors |
| Issue Date: | 1-Dec-2021 |
| Publisher: | BMJ Publishing Group |
| Abstract: | The prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age. |
| Note: | Reproducció del document publicat a: https://doi.org/10.1136/jitc-2021-003644 |
| It is part of: | Journal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 12, p. e003644 |
| URI: | http://hdl.handle.net/2445/193208 |
| Related resource: | https://doi.org/10.1136/jitc-2021-003644 |
| ISSN: | 2051-1426 |
| Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 718809.pdf | 571.93 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
